Medical Devices

63 tickers in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
10x Genomics, Inc.
TXG·Healthcare
C ★★Sell
Current$59.28
Nov 8, 2026

10x Genomics could benefit from the structural expansion of spatial and single-cell biology, but weak consolidated growth, recurring operating losses, dilution, and an expensive valuation limit its investment appeal.

Score
55
MiniMed Group, Inc.
MMED·Healthcare
F Avoid
Current$22.50
Sep 14, 2026

MiniMed has a credible diabetes-technology growth engine led by Flex, CGM attachment and a strong pipeline, but negative free cash flow, low current returns and an expensive forward multiple make the post-spin risk-reward unattractive today.

Score
44
GRAIL, Inc.
GRAL·Healthcare
F Avoid
Current$121.44
Nov 7, 2026

GRAIL offers substantial long-term growth potential through Galleri's multi-cancer screening technology and pending FDA approval, but weak operating economics, persistent cash burn, dilution, and demanding valuation undermine its current risk-reward profile.

Score
38